Status:
COMPLETED
Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis
Lead Sponsor:
Universita di Verona
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18+ years
Brief Summary
This was a retrospective, observational study. The objective of the study is investigate the efficacy and safety of secukinumab without the initial weekly loading dose in patients with chronic plaque ...
Eligibility Criteria
Inclusion
- Patients older than 18 years old
- Patients with moderate to severe chronic plaque psoriasis treated with secukinumab with or without initial loading dose for at least 48 week
- The criteria for receiving secukinumab were according to standard clinical practice.
Exclusion
- Patients younger than 18 years old
- Patients with only psoriatic arthritis or with other forms of psoriasis than chronic plaque type (such as drug-induced psoriasis or guttate, erythrodermic, or pustular psoriasis)
- Pregnant women and women during breastfeeding
Key Trial Info
Start Date :
March 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 12 2019
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT03828643
Start Date
March 20 2019
End Date
April 12 2019
Last Update
April 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Verona
Verona, Italy, 37126